Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002

The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood.

In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.

Inclusion Criteria:

• Age > 18 years
• Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade
• Signed informed consent
• Affiliated to(or beneficiary of) the French Social Security

Exclusion Criteria:

• Pregnant or breastfeeding woman or woman who does not apply effective contraception
• Emergency
• Vulnerable person or unable to provide informed consent
• Emergency
• Person unable to comply with required study follow up
• Contraindication to the study procedure